Review article: remission rates achievable by current therapies for inflammatory bowel disease
- 15 February 2011
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 33 (8), 870-879
- https://doi.org/10.1111/j.1365-2036.2011.04599.x
Abstract
International audienceBackground and Aim: To review remission rates with current medical treatments for inflammatory bowel disease (IBD). Methods We searched MEDLINE (source PUBMED, 1966 to January, 2011). Results Induction and maintenance of remission was observed in 20% (range, 9-29.5%) and 53% (range, 36.8-59.6%) of ulcerative colitis (UC) patients treated with oral 5-ASA derivatives. Induction of remission was noted in 52% (range, 48-58%) of Crohn's disease (CD) patients and 54% of UC patients treated with steroids in population-based cohorts. Maintenance of remission was reported in 71% (range, 56-95%) of CD patients on azathioprine over a 6 month to 2 year period and in 60% (range, 41.7-82.4%) in UC at one year or longer. Induction and maintenance of remission was noted in 39% (range, 19.3-66.7%) and 70% (range, 39-90%) of CD patients on methotrexate over a 40 week period. Induction of remission was reported in 32% (range, 25-48%), 26% (range, 18-36%) and 20% (range, 19-23%) of CD patients on infliximab, adalimumab and certolizumab pegol, respectively. The corresponding figures were 45% (range, 39-59%), 43% (range, 40-47%) and 47.9% at weeks 20-30 among initial responders. Induction of remission was observed in 33% (range, 27.5-38.8%) and 18.5% of UC patients on infliximab and adalimumab, respectively. Maintenance of remission was noted in 33% (range, 25.6-36.9%) of UC patients on infliximab at week 30. Approximately one-fifth of CD and UC patients treated with biologicals require intestinal resection after 2-5 years in referral-center studies. Conclusion In the era of biologics, the proportion of patients not entering remission remains highKeywords
This publication has 70 references indexed in Scilit:
- The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current managementJournal of Crohn's and Colitis, 2010
- Management of Crohn's Disease in AdultsThe American Journal of Gastroenterology, 2009
- Use of new once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis: Is there anything new under the sun?World Journal of Gastroenterology, 2009
- Defining the Optimal Response Criteria for the Crohn's Disease Activity Index for Induction Studies in Patients With Mildly to Moderately Active Crohn's DiseaseThe American Journal of Gastroenterology, 2008
- European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosisJournal of Crohn's and Colitis, 2008
- A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative ColitisGastroenterology, 2007
- Delayed-Release Oral Mesalamine 4.8 g/day (800 mg tablets) Compared with 2.4 g/day (400 mg tablets) for the Treatment of Mildly to Moderately Active Ulcerative Colitis: The ASCEND I TrialCanadian Journal of Gastroenterology, 2007
- Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled studyGut, 2005
- Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's diseasePublished by Wiley ,2005
- A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's diseaseGastroenterology, 2002